Date of Award
Open Access Thesis
Master of Medical Science (MMSc)
F. Perry Wilson, MD, MSCE
Metabolic syndrome is a critical risk factor for the development of type 2 diabetes mellitus and cardiovascular disease, two of the leading causes of death in the United States. With over one third of the adult population currently affected, this syndrome poses a serious health and economic burden. Lifestyle modification is the primary treatment, however only 50% maintain adherence. A single pharmacological therapy such as canagliflozin may overcome this lack of treatment adherence. Our purpose is to establish a difference between canagliflozin 300 milligrams daily plus lifestyle modification education and lifestyle modification education alone for the remission of metabolic syndrome in nondiabetic adults after one year. We will conduct a double-blind, randomized placebo-controlled trial in order to assess for this primary endpoint. This study has the capability to improve the current treatment of metabolic syndrome and potentially prevent the development of type 2 diabetes mellitus and cardiovascular disease.
Asseo, Corrie, "Administration of Canagliflozin for the Remission of Metabolic Syndrome in Nondiabetic Adults" (2020). Yale School of Medicine Physician Associate Program Theses. 2.
This Article is Open Access